Endotoxin apheresis for sepsis

Shimizu, Tomoharu; Endo, Yuichi; Tsuchihashi, Hiroshi; Akabori, Hiroya; Yamamoto, Hiroshi; Tani, Tohru

doi:10.1016/j.transci.2006.06.006

Cited by 26 publications

(15 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An antilipopolysaccharide monoclonal antibody has been developed against endotoxin, and experimental and clinical studies have been performed; however, clinical trials have been rather unsuccessful [7]. Strategies for removing endotoxin from the bloodstream have been described and clinically applied for the treatment of sepsis [8]. Polymyxin B is a polycationic antibiotic with a well-established action of specific binding to endotoxin resulting in neutralization of its toxicity.…”

Section: Introductionmentioning

confidence: 99%

“…Tani et al [9] were the first to develop a method of absorbing endotoxin in the blood by a polymyxin-Bimmobilized fiber column (Toraymyxin®). Direct hemoperfusion with a polymyxin-B-immobilized fiber column (PMX) has been used clinically for the treatment of septic shock in over 30,000 patients under the Japanese National Health Insurance system since 1994 [8,10]. Some beneficial effects of this approach have been demonstrated in clinical studies for the treatment of severe sepsis or septic shock [11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Direct hemoperfusion with polymyxin-B-immobilized fiber columns improves septic hypotension and reduces inflammatory mediators in septic patients with colorectal perforation

Shimizu

Hanasawa

Sato

et al. 2008

Langenbecks Arch Surg

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Direct hemoperfusion with polymyxin-B-immobilized fiber columns improves septic hypotension and reduces inflammatory mediators in septic patients with colorectal perforation

Shimizu

Hanasawa

Sato

et al. 2008

Langenbecks Arch Surg

Self Cite

View full text Add to dashboard Cite

show abstract

“…This limitation has been overcome by a mechanism which takes advantage of polymyxin without exposing the patient to its systemic effects. Polymyxin B-immobilized fiber hemoperfusion (PMX-DHP) is the only extracorporeal device reported to be safe and effective in septic patients [2][3][4][5].…”

Section: Introductionmentioning

confidence: 99%

Polymixin-B hemoperfusion in a case intolerant to conventional antibiotic therapy

Novelli¹,

Morabito²,

Ferretti³

et al. 2012

JBiSE

View full text Add to dashboard Cite

In this study we document how it was possible to resolve the septic complications of abdominal surgery, subjecting a patient severely allergic to intravenous antibiotics. We performed the hemoperfusion with polymyxin-B columns (PMX-DHP), guiding the therapy by assaying endotoxin activity and evaluating the clinical status of the patient after each session of PMX-DHP. The stabilization of hemodynamic and inflammatory frameworks were immediately observed after the PMX-DHP. The patient could be safely discharged five days after the discontinuation of the therapy. Our findings confirms data already published in literature concerning the effectiveness of PMX-DHP.

show abstract

“…This review does not concentrate on the extracorporeal removal of endotoxin in vivo, which is the subject of other reviews (21)(22)(23).…”

Section: Introductionmentioning

confidence: 99%

Lipopolysaccharide,LPSremoval, Depyrogenation

Magalhães

Pessoa

2010

Encyclopedia of Industrial Biotechnology

View full text Add to dashboard Cite

Advances in biotechnology have opened up numerous possibilities for the large‐scale production of many biomolecules that are important for research, pharmaceuticals, and industrial applications. The development of techniques and methods for the separation and purification of proteins and other biomolecules has been of paramount importance for many of these advances in the biotechnology industry. Such biomolecules may be expressed as soluble extracellular form, soluble intracellular form, or as membrane constitute or inclusion bodies. In all three cases, use of cellular rupture procedures for the recovery of the biomolecules of interest, which lead to the release of a large quantity of lipopolysaccharide (LPS)‐type endotoxins, is necessary. The presence of small amounts of endotoxin in recombinant protein preparations can cause side effects such as endotoxin shock, tissue injury, and even death in host organism. Owing to these reactions, research on the methods used to remove endotoxins from drugs, injectables, and other biological and pharmaceutical products is necessary. Taking into consideration the main techniques used as well as the state of the art of the technology in this field, the techniques of endotoxin determination and interaction of endotoxins with proteins are presented.

show abstract

Endotoxin apheresis for sepsis

Cited by 26 publications

References 46 publications

Direct hemoperfusion with polymyxin-B-immobilized fiber columns improves septic hypotension and reduces inflammatory mediators in septic patients with colorectal perforation

Direct hemoperfusion with polymyxin-B-immobilized fiber columns improves septic hypotension and reduces inflammatory mediators in septic patients with colorectal perforation

Polymixin-B hemoperfusion in a case intolerant to conventional antibiotic therapy

Lipopolysaccharide,LPSremoval, Depyrogenation

Contact Info

Product

Resources

About